Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 11:58 AM ET


Company Overview of Incyte Corporation

Executive Profile

David W. Gryska MBA

Chief Financial Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 12 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. David W. Gryska, also known as Dave, MBA, has been the Chief Financial Officer and Executive Vice President of Incyte Corporation since October 31, 2014. Mr. Gryska has been Strategic Advisor to the Board at Novogen Limited since March 3, 2014. Mr. Gryska served as an Interim Chief Executive Officer of Myrexis Inc., from August 15, 2012 to December 24, 2012. He served as the Chief Operating Officer of Myrexis, Inc., from May 11, 2012 to December 24, 2012 and served ...

Corporate Headquarters

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships

Independent Director and Chairman of Audit Committee
Director and Chairman of Audit Committee
Director, Member of Audit Committee and Member of Nominating & Governance Committee


Unknown/Other Education
Golden Gate University
Loyola University of Chicago
Doctorate2010 - 2010
Jawaharlal Nehru Technological University

Other Affiliations

Annual Compensation

Total Annual Compensation$113,788

Stocks Options

Restricted Stock Awards$524,946
All Other Compensation$30,645
Unexercisable Options$55,376
Unexercisable Options Value$335,025
Total Value of Options$335,024
Total Number of Options$55,376

Total Compensation

Total Annual Cash Compensation$208,522
Total Short Term Compensation$113,788
Other Long Term Compensation$555,591
Total Calculated Compensation$2,308,442

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
Paris Panayiotopoulos Chief Executive Officer, President and Director
Ariad Pharmaceuticals Inc.
Jean-Jacques Bienaime MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Incyte Corporation, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at